Vaccination against feline viral rhinotracheitis in kittens with maternally derived feline viral rhinotracheitis antibodies.
The efficacy of a modified live-virus intranasal vaccine and a killed-virus adjuvanted parenteral vaccine in inducing protective immunity against feline viral rhinotracheitis (FVR) was evaluated in kittens with and without maternally derived FVR antibodies. The intranasal vaccine was given as a single dose to kittens 5 weeks old, and the parenteral vaccine was administered in 2 doses at 5 and 7 weeks of age. Seroconversion was delayed for 5 to 10 days in kittens with maternally derived antibodies, but occurred in all vaccinated kittens by 8 weeks of age. When virulent FVR virus was given, both vaccines provided satisfactory protection against disease but did not prevent infection. The results indicated that the modified live-virus intranasal vaccine or the killed-virus adjuvanted parenteral vaccine can be used successfully in kittens with residual maternally derived FVR antibodies.
Johnson
R P
RP
Povey
R C
RC
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002371:Cat Diseases / Q000517:prevention & control*; D002415:Cats; D006564:Herpesviridae / Q000276:immunology*; D006566:Herpesviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D007112:Immunity, Maternally-Acquired; D009500:Neutralization Tests / Q000662:veterinary; D012141:Respiratory Tract Infections / Q000517:prevention & control / Q000662:veterinary*; D014611:Vaccination / Q000662:veterinary*; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines